Why a Chinese Agent Is Legally Required for Registration
China’s regulatory framework treats a foreign medical device manufacturer as an “overseas applicant” (境外申请人, jìngwài shēnrén qǐngrén). NMPA does not accept registration submissions directly from an address outside mainland China. The rationale is enforcement: regulators need a local entity that can be held accountable for post-market surveillance, adverse event reporting, and product recall obligations.
The Chinese Agent must be a company registered under Chinese law, with a physical business address in mainland China. This agent files the application on behalf of the foreign manufacturer, receives NMPA correspondence, and bears joint legal responsibility for the device’s compliance. The manufacturer-agent relationship must be documented via a legally notarized Power of Attorney (授权书, shòuquán shū).
According to NMPA’s 2023 annual report, 1,472 foreign medical device products received registration certificates that year. Every single one was processed through a designated Chinese Agent. No direct overseas filings were accepted. This is a non-negotiable requirement for all three device classes.
Options: Using a Chinese Agent vs. Establishing a Wholly Foreign-Owned Enterprise (WFOE)
Foreign companies have two main structural paths. The first is appointing a third-party Chinese Agent — typically a regulatory consulting firm, a trading company, or a local distributor. This is the fastest and lowest-cost route, suitable for companies with limited China sales volume or those testing the market.
The second path is establishing a Wholly Foreign-Owned Enterprise (外商独资企业, wàishāng dúzī qǐyè), or WFOE, in China. This entity then acts as the manufacturer’s own Chinese Agent. A WFOE gives the foreign company direct control over the registration process, supply chain, and brand reputation. However, incorporation takes 3–6 months, requires registered capital of at least USD 100,000–500,000 depending on the city, and demands ongoing compliance with China’s corporate and tax laws.
The table below summarizes the key differences between these two approaches for a typical Class II medical device registration.
| Factor | Third-Party Chinese Agent | WFOE as Chinese Agent |
|---|---|---|
| Setup time | 1–2 months | 3–6 months |
| Upfront cost (USD) | 15,000–40,000 | 100,000–500,000 |
| Control over registration | Shared | Full |
| Post-market liability | Agent bears joint liability | Manufacturer’s own entity bears liability |
| Data confidentiality | Shared with agent | Retained in-house |
| Best for | Low-volume, market testing | High-volume, strategic market |
Many foreign companies start with a third-party agent and later transition to a WFOE once annual China revenue exceeds USD 2–3 million. That inflection point typically makes the investment in a local entity cost-effective due to retained profits and brand leverage.
Timeline and Cost: From Submission to NMPA Approval
The registration timeline depends heavily on device classification. China uses three classes: Class I (low risk, filed with local Municipal Medical Products Administration), Class II (medium risk, reviewed by provincial NMPA bureaus), and Class III (high risk, reviewed by central NMPA in Beijing). For foreign manufacturers, Class II and III devices must undergo NMPA’s standard review process regardless of risk level — Class I foreign devices also require central filing, unlike domestic Class I.
A typical Class II foreign device registration takes 12–18 months from document preparation to certificate issuance. Class III devices take 18–36 months, especially if they require a clinical trial within China or an expert panel review. The NMPA review period alone is 90 working days for Class II and 120 working days for Class III, but clock pauses for document corrections add significant time.
Cost estimates from China Gateway 360’s 2024 regulatory benchmark survey show the following averages for foreign manufacturers using a third-party agent:
- Class I filing: USD 5,000–10,000; timeline 4–8 months
- Class II registration: USD 30,000–80,000; timeline 12–18 months
- Class III registration (no clinical trial): USD 80,000–150,000; timeline 18–24 months
- Class III registration (with China clinical trial): USD 200,000–500,000; timeline 24–36 months
These figures include NMPA review fees, Chinese Agent service fees, document translation and notarization, testing at China-authorized laboratories, and quality system audits if required. NMPA’s own official review fee for a Class II foreign device is approximately USD 2,500, and for Class III approximately USD 4,000 — but these are a small fraction of the total cost.
Do You Need a China Clinical Trial? The Two Exceptions
Many foreign manufacturers worry about the requirement for a clinical trial in China. The good news is that NMPA accepts clinical data from overseas clinical trials under certain conditions. Since 2018, NMPA has allowed foreign clinical data to support registration if the trial was conducted according to Good Clinical Practice (GCP) standards and the data are applicable to the Chinese population.
However, three situations still require a China-specific clinical trial or a bridging study:
- Class III implanted devices with no prior marketing history in China — approximately 40% of such devices require a local trial.
- Novel devices (no predicate product registered in China) — NMPA often demands a confirmatory trial with Chinese subjects.
- Devices using new biomaterials where ethnic differences in tissue response cannot be ruled out.
According to NMPA’s 2023 Center for Medical Device Evaluation (CMDE) report, 62% of foreign Class III device registrations that year were approved using overseas clinical data alone, without any China-specific clinical trial. This represents a significant reduction from 2016, when only 35% avoided a local trial.
Key Documents Required for a Foreign Device Registration Application
Understanding the document package helps manage expectations. NMPA requires a comprehensive dossier that mirrors the IMDRF (International Medical Device Regulators Forum) table of contents, but with China-specific additions. The core documents include:
- Power of Attorney to the Chinese Agent (notarized and legalized)
- Free Sale Certificate from the home country government
- ISO 13485 or equivalent quality system certificate
- Product technical requirements (符合性检验报告, fúhéxìng jiǎnyàn bàogào) tested by a China-authorized laboratory
- Stability and shelf-life test reports
- Clinical evaluation report (CER) or clinical trial data
- Device label and instructions for use (Chinese language required)
- Risk management report (ISO 14971 compliant)
The testing at a China-authorized laboratory (承检机构, chéng jiǎn jīgòu) is often the longest single step. Labs such as TUV Rheinland Shanghai, SGS Shanghai, and the China National Institute for Food and Drug Control (国家药监局医疗器械技术审评中心, guójiā yàojiān jī) may have 4–6 month backlogs for standard testing. The total number of pages in a Class III submission can exceed 5,000.
Recent Regulatory Changes Affecting Foreign Manufacturers (2022–2024)
Three policy developments are particularly relevant:
First, the “Chinese Agent Accountability” Notice (2023). NMPA clarified that the Chinese Agent cannot simply be a mailbox. The agent must have qualified personnel, adequate facilities, and documented processes for adverse event handling and recall management. Several provincial NMPA offices have started on-site inspections of Chinese Agents representing foreign manufacturers.
Second, the “Priority Review” pathway (2022 revision). Devices that address an unmet medical need in China — such as innovative cancer diagnostics or rare disease devices — can qualify for priority review, reducing NMPA’s review timeline from 120 working days to 60 working days. Foreign manufacturers are eligible. In 2023, 18 foreign devices benefited from this pathway.
Third, the “Overseas Manufacturing Site Inspection” policy (2024). NMPA resumed overseas on-site inspections post-pandemic. Approximately 1 in 5 Class III foreign device applications now triggers a physical inspection of the overseas manufacturing facility by an NMPA team. This adds 2–4 months to the timeline and requires the manufacturer to have a Chinese-language quality system manual ready for review.
Frequently Asked Questions
Can a Hong Kong company act as the Chinese Agent?
No. The Chinese Agent must be a mainland China-registered entity with a physical address in mainland China. Hong Kong cannot fulfill this role.
Do I need a WFOE before I can register?
No. Many foreign manufacturers successfully register using a third-party Chinese Agent without any China entity. The WFOE is optional and strategic.
What happens if my Chinese Agent changes?
NMPA allows the transfer of registration certificates to a new agent. This requires a new Power of Attorney, a statement from the former agent confirming release, and a submission fee. The process takes 2–4 months.
Is the registration certificate renewable?
Yes. Registration certificates are valid for 5 years. Renewal applications must be filed 6 months before expiry. The renewal process is simpler than initial registration but still requires updated testing reports and a post-market surveillance summary.
Can I sell my device while the registration is pending?
No. Selling or importing a device for commercial distribution before NMPA registration is illegal. Customs will block unregistered devices at the port. Only devices with a valid NMPA registration certificate can clear customs.
NEXT STEPS
Based on your company’s situation, choose one of these three paths:
Path 1 — Market Testing (Low Volume, First Time in China)
Appoint a reputable third-party Chinese Agent with Class II/III experience. Start with one representative device to learn the process. Budget USD 40,000–80,000 for the first registration. Read our Guide to Selecting a Chinese Registration Agent for vetting criteria.
Path 2 — Strategic Entry (Medium-High Volume, Long-Term Plan)
Incorporate a WFOE in Shanghai or Beijing, then use that entity as your own Chinese Agent. This gives you control and profit retention. Budget USD 200,000–500,000 for setup and first registration. See our WFOE Setup Roadmap for Medical Device Companies.
Path 3 — Fast-Track for Innovative Devices
If your device qualifies for NMPA priority review or is designated as an “innovative medical device” (创新医疗器械, chuàngxīn yīliáo qìxiè), you may reduce approval time by 30–50%. This requires a strong clinical evidence package. Contact our team at China Gateway 360 Regulatory Advisory for a pre-submission assessment.
